I read this: This prospectus relates to the off

I read this:

This prospectus relates to the offer and sale of up to 148,639,455 shares of common stock of Generex Biotechnology Corporation, by the selling stockholders. These shares consist of (i) 5,102,040 shares of our common stock that were previously issued to the selling shareholders; (ii) 48,639,456 shares of our common stock issuable upon exercise of Series A Warrants and Series B Warrants; (iii) 66,666,666 shares of our common stock issuable upon exercise of Series C Warrants; and (iv) 28,231,293 shares of our common stock issuable upon exercise of Series D Warrants.

The shares of our common stock registered hereby may be offered and sold by the selling stockholders from time to time in the over-the-counter market or other national securities exchange or automated interdealer quotation system on which our common stock is then listed or quoted, or through one or more underwriters, broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of common stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See “Plan of Distribution.”

We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders. We will, however, receive proceeds from the exercise of the Warrants if and when they are exercised in cash. See “Use of Proceeds.”



We will pay the expenses incurred in registering the shares, including legal and accounting fees. See “Plan of Distribution.”



Our common stock is quoted on the OTCQB under the symbol “GNBT.” On August 19, 2020, the last reported sale price of our common stock on the OTCQB was $0.465.